Search

Your selection

None

Filter by content type

Filter by content year

News

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

May 14, 2025 - … Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding Machine … statistically significant correlates of protection and will be incorporated into the development of Vaxart’s … show that the trial met five of its six primary endpoints and demonstrate the safety, efficacy, and immunogenicity of …
News

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

March 5, 2025 - … Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus … Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus … Translational Medicine . The data, which show strong and durable antibody responses and induction of …
News

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

August 8, 2024 - … Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results August 8, … as a next-generation approach to combating COVID-19 and future pandemic threats Solid financial position enables …
News

Vaxart Provides Business Update

June 17, 2024 - … well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs — SOUTH SAN FRANCISCO, Calif. , June … -- Vaxart, Inc. (Nasdaq: VXRT) today provided business and cash runway updates as the Company continues to advance …
News

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

May 13, 2024 - … Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results May 13, 2024 … meeting with the FDA in mid-2024 to evaluate clinical data and discuss next steps for its norovirus program Conference …
News

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

April 30, 2024 - … 2024 Earnings Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide … rose on average 4.0 fold for the G1.1 virus strain and 6.0 fold for the GII.4 virus strain in the breast milk of … were no vaccine-related serious adverse events (SAEs) and no dose-limiting pharmacotoxicity. “This is an important …
News

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

March 14, 2024 - … Vaxart Provides Business Update and Reports Full Year 2023 Financial Results Vaxart Provides Business Update and Reports Full Year 2023 Financial Results March 14, 2024 … Steven Lo appointed President, Chief Executive Officer and Board Member Conference call today at 4:30 p.m. ET SOUTH …
News

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

December 21, 2023 - … VXRT) today announced that it has completed enrollment and dosing in the Phase 1 clinical trial evaluating Vaxart’s … to protect their children against this highly contagious – and potentially lethal -- virus. We look forward to … 21 million people in the United States each year, and 15% of children under age 5 contract norovirus annually. …
News

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

November 2, 2023 - … Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results November 2, … of norovirus infection, norovirus acute gastroenteritis and viral shedding Clinical proof of concept for the …
News

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

November 2, 2023 - … of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN … 21 million people in the United States each year, and 15% of children under age 5 contract norovirus annually. … study is designed to evaluate the safety, tolerability, and immunogenicity of orally administered bivalent GI.1/GII.4 …
Scroll to Top